## **Andreas Teufel**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1415038/publications.pdf

Version: 2024-02-01

109321 88630 5,393 121 35 70 citations h-index g-index papers 127 127 127 9849 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	DNA Methylation Analysis in Nonalcoholic Fatty Liver Disease Suggests Distinct Disease-Specific and Remodeling Signatures after Bariatric Surgery. Cell Metabolism, 2013, 18, 296-302.	16.2	424
2	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 2013, 45, 670-675.	21.4	339
3	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics, 2017, 49, 269-273.	21.4	230
4	Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nature Genetics, 2011, 43, 17-19.	21.4	221
5	Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. Journal of Hepatology, 2012, 57, 366-375.	3.7	196
6	Concurrent Autoimmune Diseases in Patients With Autoimmune Hepatitis. Journal of Clinical Gastroenterology, 2010, 44, 208-213.	2.2	181
7	Comparison of Gene Expression Patterns Between Mouse ModelsÂof Nonalcoholic Fatty Liver Disease and Liver TissuesÂFrom Patients. Gastroenterology, 2016, 151, 513-525.e0.	1.3	180
8	Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut, 2012, 61, 1733-1743.	12.1	159
9	Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. Journal of Hepatology, 2012, 56, 267-275.	3.7	150
10	Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at <i>GPR35</i> and <i>TCF4</i> . Hepatology, 2013, 58, 1074-1083.	7.3	150
11	Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis. Journal of Clinical Gastroenterology, 2009, 43, 489-495.	2.2	146
12	Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology, 2013, 58, 1054-1064.	7.3	138
13	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score. Journal of Hepatology, 2022, 76, 353-363.	3.7	132
14	Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology, 2009, 49, 627-636.	7.3	130
15	Frcp1 and Frcp2, two novel fibronectin type III repeat containing genes. Gene, 2002, 297, 79-83.	2.2	122
16	Genetics of hepatocellular carcinoma. World Journal of Gastroenterology, 2007, 13, 2271.	3.3	116
17	Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology, 2010, 51, 1226-1236.	7.3	106
18	Mutational Characterization of the Bile Acid Receptor TGR5 in Primary Sclerosing Cholangitis. PLoS ONE, 2010, 5, e12403.	2.5	106

#	Article	IF	CITATIONS
19	Intraflagellar transport protein 172 is essential for primary cilia formation and plays a vital role in patterning the mammalian brain. Developmental Biology, 2009, 325, 24-32.	2.0	100
20	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut, 2019, 68, 1099-1107.	12.1	100
21	TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death and Disease, 2020, 11, 212.	6.3	90
22	Tumorâ€infiltrating, interleukinâ€33–producing effectorâ€memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology, 2015, 61, 1957-1967.	7.3	84
23	Chemotherapyâ€induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated <i>via</i> the extrinsic and the intrinsic pathway. International Journal of Cancer, 2010, 126, 2049-2066.	5.1	78
24	IFN-α–Induced Apoptosis in Hepatocellular Carcinoma Involves Promyelocytic Leukemia Protein and TRAIL Independently of p53. Cancer Research, 2009, 69, 855-862.	0.9	73
25	Hepatocellular carcinoma in patients with autoimmune hepatitis. World Journal of Gastroenterology, 2009, 15, 578.	3.3	64
26	Pregnancy in primary sclerosing cholangitis. Gut, 2011, 60, 1117-1121.	12.1	63
27	Translating bioinformatics in oncology: guilt-by-profiling analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis. Bioinformatics, 2015, 31, 216-224.	4.1	63
28	Liver specific overexpression of plateletâ€derived growth factorâ€B accelerates liver cancer development in chemically induced liver carcinogenesis. International Journal of Cancer, 2011, 128, 1259-1268.	5.1	59
29	Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. Gene, 2008, 423, 23-28.	2.2	52
30	Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. Cells, 2021, 10, 648.	4.1	47
31	Association of autoimmune hepatitis and systemic lupus erythematodes: A case series and review of the literature. World Journal of Gastroenterology, 2014, 20, 12662.	3.3	42
32	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	12.1	42
33	Advanced Mucinous Colorectal Cancer: Epidemiology, Prognosis and Efficacy of Chemotherapeutic Treatment. Digestion, 2018, 98, 143-152.	2.3	40
34	Management of immune related adverse events induced by immune checkpoint inhibition. Cancer Letters, 2019, 456, 80-87.	7.2	36
35	Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation (i) in vitro (i) and in mice. Oncotarget, 2017, 8, 13059-13072.	1.8	35
36	The longevity assurance homologue of yeast lag1 (Lass) gene family (review). International Journal of Molecular Medicine, 2009, 23, 135-40.	4.0	35

#	Article	IF	CITATIONS
37	Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World Journal of Gastroenterology, 2009, 15, 449.	3.3	34
38	Irreversible Electroporation of Malignant Hepatic Tumors - Alterations in Venous Structures at Subacute Follow-Up and Evolution at Mid-Term Follow-Up. PLoS ONE, 2015, 10, e0135773.	2.5	32
39	Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy?. World Journal of Gastroenterology, 2007, 13, 3605.	3.3	32
40	Bioinformatics and database resources in hepatology. Journal of Hepatology, 2015, 62, 712-719.	3.7	31
41	TGF-Î <sup>2</sup> 2 silencing to target biliary-derived liver diseases. Gut, 2020, 69, 1677-1690.	12.1	31
42	Microarray-Based Gene Expression Analysis of Hepatocellular Carcinoma. Current Genomics, 2010, 11, 261-268.	1.6	30
43	Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer. Journal of Clinical Investigation, 2020, 130, 2509-2526.	8.2	29
44	Current bioinformatics tools in genomic biomedical research (Review). International Journal of Molecular Medicine, 2006, 17, 967-73.	4.0	29
45	Metabolomic tissue signature in human nonâ€alcoholic fatty liver disease identifies protective candidate metabolites. Liver International, 2015, 35, 207-214.	3.9	28
46	Update on autoimmune hepatitis. World Journal of Gastroenterology, 2009, 15, 1035.	3.3	28
47	Impact of Direct Acting Antiviral (DAA) Treatment on Glucose Metabolism and Reduction of Pre-diabetes in Patients with Chronic Hepatitis C. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 281-289.	0.9	27
48	Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab. Seminars in Arthritis and Rheumatism, 2020, 50, 1087-1088.	3.4	26
49	î"Np73î² is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle, 2010, 9, 2629-2639.	2.6	25
50	Spatio-Temporal Multiscale Analysis of Western Diet-Fed Mice Reveals a Translationally Relevant Sequence of Events during NAFLD Progression. Cells, 2021, 10, 2516.	4.1	24
51	Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival. Oncotarget, 2017, 8, 71002-71011.	1.8	24
52	Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients. World Journal of Gastroenterology, 2006, 12, 5513.	3.3	23
53	Liverâ€specific overexpression of matrix metalloproteinase 9 (MMPâ€9) in transgenic mice accelerates development of hepatocellular carcinoma. Molecular Carcinogenesis, 2012, 51, 439-448.	2.7	23
54	Causal Modeling of Cancer-Stromal Communication Identifies PAPPA as a Novel Stroma-Secreted Factor Activating NFήB Signaling in Hepatocellular Carcinoma. PLoS Computational Biology, 2015, 11, e1004293.	3.2	22

#	Article	IF	CITATIONS
55	Actin binding LIM protein 3 (abLIM3). International Journal of Molecular Medicine, 2006, 17, 129-33.	4.0	21
56	Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration. Journal of Hepatology, 2012, 56, 279-281.	3.7	19
57	A systems biology perspective on cholangiocellular carcinoma development: Focus on MAPK-signaling and the extracellular environment. Journal of Hepatology, 2009, 50, 1122-1131.	3.7	18
58	Next generation sequencing of the Ago2 interacting transcriptome identified chemokine family members as novel targets of neuronal microRNAs in hepatic stellate cells. Journal of Hepatology, 2013, 58, 335-341.	3.7	18
59	Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer. BMC Cancer, 2015, 15, 419.	2.6	18
60	Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. Cellular Oncology (Dordrecht), 2019, 42, 705-715.	4.4	18
61	Severe Dysbiosis and Specific <i>Haemophilus</i> and <i>Neisseria</i> Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients. Clinical Infectious Diseases, 2022, 75, e1063-e1071.	5.8	18
62	Liver-specific Ldb1 deletion results in enhanced liver cancer development. Journal of Hepatology, 2010, 53, 1078-1084.	3.7	16
63	Obeticholic Acid Inhibits Anxiety via Alleviating Gut Microbiota-Mediated Microglia Accumulation in the Brain of High-Fat High-Sugar Diet Mice. Nutrients, 2021, 13, 940.	4.1	16
64	CellMiner <scp>HCC</scp> : a microarrayâ€based expression database for hepatocellular carcinoma cell lines. Liver International, 2014, 34, 621-631.	3.9	15
65	Random gene sets in predicting survival of patients with hepatocellular carcinoma. Journal of Molecular Medicine, 2019, 97, 879-888.	3.9	15
66	BMP-9 Modulates the Hepatic Responses to LPS. Cells, 2020, 9, 617.	4.1	15
67	Contrast enhanced ultrasound in mixed hepatocellular cholangiocarcinoma: Case series and review of the literature. Digestive and Liver Disease, 2018, 50, 401-407.	0.9	14
68	Benefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4NOMO colon cancer. European Journal of Cancer, 2020, 137, 148-160.	2.8	14
69	Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1033-1050.	2.5	14
70	Follistatinâ€controlled activinâ€HNF4αâ€coagulation factor axis in liver progenitor cells determines outcome of acute liver failure. Hepatology, 2022, 75, 322-337.	7.3	14
71	LASS6, an additional member of the longevity assurance gene family. International Journal of Molecular Medicine, 2005, 16, 905-10.	4.0	14
72	Post-COVID-19 Impairment of the Senses of Smell, Taste, Hearing, and Balance. Viruses, 2022, 14, 849.	3.3	14

#	Article	lF	CITATIONS
73	Predictive Scores in Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2015, 49, 438-447.	2.2	12
74	Conventional ultrasound for diagnosis of hepatic steatosis is better than believed. Zeitschrift Fur Gastroenterologie, 2022, 60, 1235-1248.	0.5	12
75	In silico characterization of LZTS3, a potential tumor suppressor. Oncology Reports, 2005, 14, 547-51.	2.6	12
76	Mbx, a novel mouse homeobox gene. Development Genes and Evolution, 2002, 212, 104-106.	0.9	11
77	Snapshot liver transcriptome in hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 990-992.	3.7	11
78	Next generation sequencing of HCC from European and Asian HCC cohorts. Back to p53 and Wnt/ $I^2$ -catenin. Journal of Hepatology, 2013, 58, 622-624.	3.7	11
79	Ustekinumab serum concentrations are associated with clinical outcomes in Crohn's disease – a regional multi-center pilot study. Zeitschrift Fur Gastroenterologie, 2020, 58, 439-444.	0.5	11
80	Collecting evidence for a stem cell hypothesis in HCC. Gut, 2010, 59, 870-871.	12.1	10
81	Identification of RARRES1 as a core regulator in liver fibrosis. Journal of Molecular Medicine, 2012, 90, 1439-1447.	3.9	10
82	Hepatic Smad7 overexpression causes severe iron overload in mice. Blood, 2018, 131, 581-585.	1.4	10
83	Current Opinion about Hepatocellular Carcinoma <10 mm. Digestion, 2021, 102, 335-341.	2.3	10
84	Surveillance of hepatocellular carcinoma by medical imaging. Quantitative Imaging in Medicine and Surgery, 2019, 9, 1904-1910.	2.0	9
85	Co-Medication and Nutrition in Hepatocellular Carcinoma: Potentially Preventative Strategies in Hepatocellular Carcinoma. Digestive Diseases, 2021, 39, 526-533.	1.9	9
86	Treatment of Advanced Gastric Cancer with Etoposide, Folinic Acid, and Fluorouracil in the Clinical Setting. Medical Oncology, 2002, 19, 43-54.	2.5	8
87	Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. PLoS ONE, 2015, 10, e0140525.	2.5	8
88	Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure. Zeitschrift Fur Gastroenterologie, 2020, 58, 773-777.	0.5	8
89	RASSF1A independence and early galectinâ€1 upregulation in PIK3CAâ€induced hepatocarcinogenesis: new therapeutic venues. Molecular Oncology, 2022, 16, 1091-1118.	4.6	8
90	Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation. Hepatology, 2017, 65, 2074-2089.	<b>7.</b> 3	7

#	Article	IF	CITATIONS
91	EpiCO (epirubicin, cyclophosphamide and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms. Zeitschrift Fur Gastroenterologie, 2020, 58, 133-136.	0.5	7
92	Clinical Decision Support Systems. Visceral Medicine, 2021, 37, 491-498.	1.3	7
93	Genome-wide analysis of factors regulating gene expression in liver. Gene, 2007, 389, 114-121.	2.2	6
94	Pharmacological treatment of hepatocellular carcinoma with cavoatrial tumor thrombus – case series and literature review. Zeitschrift Fur Gastroenterologie, 2019, 57, 501-507.	0.5	6
95	Prognostic Significance and Functional Relevance of Olfactomedin 4 in Early-Stage Hepatocellular Carcinoma. Clinical and Translational Gastroenterology, 2020, 11, e00124.	2.5	6
96	Increased liver carcinogenesis and enrichment of stem cell properties in livers of Dickkopf 2 (Dkk2) deleted mice. Oncotarget, 2016, 7, 28903-28913.	1.8	6
97	Characterization of human gene encoding SLA/LP autoantigen and its conserved homologs in mouse, fish, fly, and worm. World Journal of Gastroenterology, 2006, 12, 902.	3.3	6
98	Familial amyloidosis: Great progress for an orphan disease. Journal of Hepatology, 2015, 62, 483-485.	3.7	5
99	Hepamine - A Liver Disease Microarray Database, Visualization Platform and Data-Mining Resource. Scientific Reports, 2020, 10, 4760.	3.3	5
100	Presence of gustatory and olfactory dysfunction in the time of the COVID-19 pandemic. BMC Infectious Diseases, 2021, 21, 612.	2.9	5
101	Evolutionary Distance Predicts Recurrence After Liver Transplantation in Multifocal Hepatocellular Carcinoma. Transplantation, 2018, 102, e424-e430.	1.0	4
102	Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk. American Journal of Physiology - Renal Physiology, 2021, 321, G252-G261.	3.4	4
103	Characterization of OEBT, a LIM protein. International Journal of Molecular Medicine, 2005, 15, 513-8.	4.0	4
104	Self-testing for liver disease – response to an online liver test questionnaire. Scandinavian Journal of Gastroenterology, 2020, 55, 67-73.	1.5	3
105	p53-Independent Induction of p21 Fails to Control Regeneration and Hepatocarcinogenesis in a Murine Liver Injury Model. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1387-1404.	4.5	3
106	Durable response with lenvatinib and pembrolizumab combination therapy in a patient with pre-treated metastatic cholangiocarcinoma. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 409-410.	0.9	3
107	Identification of liverâ€derived bone morphogenetic protein (BMP)â€9 as a potential new candidate for treatment of colorectal cancer. Journal of Cellular and Molecular Medicine, 2022, 26, 343-353.	3.6	3
108	Autoimmune Hepatitis: a Review of Established and Evolving Treatments. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 429-443.	0.9	3

#	ARTICLE	IF	CITATIONS
109	To Biopsy or Not to Biopsy: Evaluation of a Large German Cohort of Patients with Abnormal Liver Tests of Unknown Etiology. Digestion, 2014, 89, 310-318.	2.3	2
110	Semiautomated quantification of the fibrous tissue response to complex threeâ€dimensional filamentous scaffolds using digital image analysis. Journal of Biomedical Materials Research - Part A, 2021, , .	4.0	2
111	Digital Gastroenterology. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 493-496.	0.9	1
112	In silico characterization of an Iroquois family-related homeodomain protein. International Journal of Molecular Medicine, 2005, 16, 443-8.	4.0	1
113	Letter to the editor: vaccination against upper respiratory infections is a matter of survival in alcoholic liver disease. Gut, 2023, 72, 208-209.	12.1	1
114	Hepatic Functional Pathophysiology and Morphological Damage Following Severe Burns: A Systematic Review and Meta-analysis. Journal of Burn Care and Research, 2021, , .	0.4	1
115	Editorial: Systems Biology and Bioinformatics in Gastroenterology and Hepatology. Frontiers in Physiology, 2019, 10, 1438.	2.8	0
116	Digital Communication Strategies in Visceral Medicine. Visceral Medicine, 2021, 37, 1-6.	1.3	0
117	Benefit of adjuvant chemotherapy in patients with high-risk UICC II colon cancer T4N0M0: A ten-year population-based analysis of 3544 cases Journal of Clinical Oncology, 2019, 37, 628-628.	1.6	0
118	Digital Communication Strategies in Visceral Medicine. Visceral Medicine, 2021, 37, 1-3.	1.3	0
119	Regional differences: clinical practice guidelines on the management of hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2022, 11, 161-163.	1.5	0
120	Comparative response of HCC cells to sorafenib, lenvatinib, cabozantinib and regorafenib; descriptive expression analysis. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	0
121	Tumour-suppressive BMP-9 signalling in HCC. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	O